Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma

Background: Malignant melanoma is an aggressive disease. Tunlametinib (HL-085) is a potent, selective, and orally bioavailable MEK1/2 inhibitor. The objective of this study was to determine the pharmacokinetics (PK) of tunlametinib and its main metabolite M8 in patients with NRAS-mutant melanoma fol...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Qian, Wang, Teng, Wang, Huanhuan, Cui, Cheng, Zhong, Wen, Fu, Diyi, Xi, Wanlin, Si, Lu, Guo, Jun, Cheng, Ying, Tian, Hongqi, Hu, Pei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663925/
https://www.ncbi.nlm.nih.gov/pubmed/36386136
http://dx.doi.org/10.3389/fphar.2022.1039416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663925/
https://www.ncbi.nlm.nih.gov/pubmed/36386136
http://dx.doi.org/10.3389/fphar.2022.1039416

Ejemplares similares